title: Suppression of Th1 cytokine production by a peptide derived from C4b.
abstract: OBJECTIVE
  The complement system has been proposed to play a significant role in the regulation of T-cell responses. However, the precise mechanism underlying C4-induced immune tolerance remains to be clarified. We recently reported that monomeric C4b inhibits CXCL10 production from blood cells. The purpose of this study was to verify the active site of monomeric C4b.
  
  
  METHODS
  We investigated the in vitro effects of a C4b-derived peptide (VPAGSARPVAFSVVPTAAA), named HP2 (highly homologous peptide 2), on the IFN-β-induced production of CXCL10 in human blood and the in vivo effects of the administration of HP2 on Th1/2 cytokine production in the spleen in mice. We also tested whether the administration of HP2 influences symptoms of experimentally induced ulcerative colitis in mice.
  
  
  RESULTS
  HP2 inhibited CXCL10 production in human blood, and the administration of HP2 significantly suppressed the production of Th1 cytokines, such as IL-2, IFN-γ, and TNF-α, in spleen cells isolated from mice. The administration of HP2 in the mice significantly improved the symptoms of colitis, with down-regulation of colitogenic CD4(+)CD45RB(high) T cells and up-regulation of CD4(+)LAP/TGF-β1(+) T cells.
  
  
  CONCLUSIONS
  The amino acid sequence described above is suggested to be the active site in C4b for the inhibition of Th1 cytokine production. These results should contribute to the development of new drugs suppressing autoimmune responses.
authors: Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan.
authors: Yuji
authors: Y
authors: Takeda
authors: Kenta
authors: K
authors: Kaneda
authors: Fumie
authors: F
authors: Jimma
authors: Noriyuki
authors: N
authors: Shiobara
authors: Abbi R
authors: AR
authors: Saniabadi
authors: Ichiro
authors: I
authors: Wakabayashi
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000818:Animals; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology; D015935:Complement C4b / Q000737:chemistry*; D016207:Cytokines / Q000276:immunology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D013154:Spleen / Q000166:cytology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology; D023084:alpha-Defensins
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D010455:Peptides; D023084:alpha-Defensins; C406416:human neutrophil peptide 2; D015935:Complement C4b
references: Eur J Immunol. 2002 Sep;32(9):2672-9
references: 12207352
references: Nat Rev Immunol. 2004 Oct;4(10):825-31
references: 15459673
references: J Immunol. 2008 Oct 1;181(7):4780-90
references: 18802081
references: Annu Rev Immunol. 2004;22:431-56
references: 15032584
references: N Engl J Med. 2001 Apr 5;344(14):1058-66
references: 11287977
references: Protein Sci. 1997 Feb;6(2):263-74
references: 9041627
references: J Exp Med. 2000 Nov 6;192(9):1339-52
references: 11067882
references: Immunol Res. 2007;38(1-3):319-32
references: 17917039
references: J Immunol. 2010 Oct 15;185(8):4738-49
references: 20844193
references: Int Immunol. 1993 Nov;5(11):1461-71
references: 7903159
references: Therap Adv Gastroenterol. 2011 Sep;4(5):311-23
references: 21922030
references: J Exp Med. 2011 May 9;208(5):1027-40
references: 21518800
references: J Exp Med. 1996 Jun 1;183(6):2669-74
references: 8676088
references: Nat Rev Immunol. 2007 Jan;7(1):9-18
references: 17170757
references: Rheumatology (Oxford). 2005 Oct;44(10):1227-32
references: 15972354
references: Clin Exp Immunol. 2012 Jan;167(1):149-57
references: 22132894
references: J Immunol. 2003 Mar 1;170(5):2516-22
references: 12594277
references: Clin Exp Immunol. 2006 Nov;146(2):330-8
references: 17034586